# US 2024/0254235 A1 · Compositions and methods for treating lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254235 A1
- Document ID: US20240254235A1
- Status: Published application
- Kind: A1
- Application number: 18/560,527
- Filed: 2022-05-24
- Published: 2024-08-01
- Earliest claimed: 2021-05-24
- Applicants: Astrazeneca AB
- Inventors: Anthony JARKOWSKI, III; Phillip DENNIS; Leo TRANI; Michael NEWTON; Norah SHIRE
- Web page: https://patentgrep.com/patent/US20240254235A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods for treating locally advanced (Stage III), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD-1/PD-L1 activity concurrently with chemoradiation therapy (cCRT).

## Claims

### Claim at position 1

1: A method of extending progression-free survival (PFS) in a patient with unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the anti-PD-L1 antibody is human.

### Claim at position 3 (depends on 1)

3: The method of claim 1, wherein the chemoradiation therapy is platinum-based.

### Claim at position 4 (depends on 2)

4: The method of claim 2, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

### Claim at position 5 (depends on 2)

5: The method of claim 2, wherein the human anti-PD-L1 antibody comprises:
a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and
a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and
a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and
a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and
a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.

### Claim at position 6 (depends on 2)

6: The method of claim 2, wherein the human anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.

### Claim at position 7 (depends on 1)

7: The method of claim 1, wherein treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).

### Claim at position 8 (depends on 1)

8: The method of claim 1, wherein the unresectable NSCLC is stage III and/or is locally advanced.

### Claim 9

(canceled)

### Claim at position 10 (depends on 1)

10: The method of claim 1, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.

### Claim at position 11

11: A method of increasing the overall response rate (ORR) in a patient with unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.

### Claim at position 12 (depends on 11)

12: The method of claim 11, wherein the anti-PD-L1 antibody is human.

### Claim at position 13 (depends on 11)

13: The method of claim 11, wherein the chemoradiation therapy is platinum-based.

### Claim at position 14 (depends on 12)

14: The method of claim 12, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

### Claim at position 15 (depends on 12)

15: The method of claim 12, wherein the human anti-PD-L1 antibody comprises:
a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and
a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and
a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and
a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and
a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.

### Claim at position 16 (depends on 12)

16: The method of claim 12, wherein the human anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.

### Claim at position 17 (depends on 11)

17: The method of claim 11, wherein
treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).

### Claim at position 18 (depends on 11)

18: The method of claim 11, wherein the unresectable NSCLC is stage III and/or locally advanced.

### Claim 19

(canceled)

### Claim at position 20 (depends on 11)

20: The method of claim 11, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.

### Claim at position 21

21: A method of treating a patient with stage III unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.

### Claim at position 22 (depends on 21)

22: The method of claim 21, wherein the anti-PD-L1 antibody is human.

### Claim at position 23 (depends on 21)

23: The method of claim 21, wherein the chemoradiation therapy is platinum-based.

### Claim at position 24 (depends on 22)

24: The method of claim 22, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

### Claim at position 25 (depends on 22)

25: The method of claim 22, wherein the human anti-PD-L1 antibody comprises:
a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and
a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and
a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and
a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and
a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.

### Claim at position 26 (depends on 22)

26: The method of claim 22, wherein the anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.

### Claim at position 27 (depends on 21)

27: The method of claim 21, wherein treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).

### Claim at position 28 (depends on 21)

28: The method of claim 21, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.

### Claim at position 29

29-43. (canceled)
